Navigation Links
Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
Date:11/23/2009

ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of Librax®. Oceanside has received its first orders and expects to be a significant player in the Librax® generic market.

"Valeant's Oceanside unit has become an important division of our U.S. business with its successful launch and distribution of 5% fluorouracil, Valeant's authorized generic of Efudex®," stated J. Michael Pearson, chairman and chief executive officer. "Oceanside currently maintains a 55% market share of its Efudex® AG and plans to retain this leadership position in the future. With the industry experience we have had with Efudex® AG, we believe that we can successfully grow a strong market position with the launch of Librax® AG."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding Oceanside's launch and growth of Librax AG and Oceanside's strong leadership position with Efudex AG. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.


Contact:
Laurie W. Little
Valeant Pharmaceuticals
949-461-6002
laurie.little@valeant.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

SOURCE Valeant Pharmaceuticals International


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Cognitive Computing for Cancer ... allowing a previously unattainable level of personalized treatment ... ability, it is anticipated that the Global Cancer ... by 2022. The growth of the market is ... platforms, rising installation of cognitive computing software in ...
(Date:2/21/2017)... 2017 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the ... company will release its fourth quarter and full year ... February 28, 2017. The press release will be followed ... will be open to the public via telephone and ... its financial results and provide a business update. ...
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & ... in Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon ... clinic employees, the construction team and tribal leadership. , Choctaw Nation Durant ...
(Date:2/21/2017)... ... ... Individuals who have been diagnosed with cancer are at ... management. Regular exercise in proper environments has been shown to benefit these patients, ... 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx webinar led by ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each ... Black History Month (officially African American History Month ). This ... society of a diverse race of people, but also the opportunity to examine ...
(Date:2/21/2017)... ... February 21, 2017 , ... CLICKco LLC, a company dedicated ... are now available for purchase on RonnieColemanNutrition.com, a popular website for health and ... health-conscious consumers who love coffee but are looking to add more protein to ...
(Date:2/20/2017)... Raton, FL (PRWEB) , ... February 20, 2017 ... ... creating a patent-pending probiotic supplement that supports the proper levels of “good” bacteria ... purchase on StackedNutrition.com, a popular nutritional products website. , Daily Body Restore® ...
Breaking Medicine News(10 mins):